JP2013520979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520979A5 JP2013520979A5 JP2012555437A JP2012555437A JP2013520979A5 JP 2013520979 A5 JP2013520979 A5 JP 2013520979A5 JP 2012555437 A JP2012555437 A JP 2012555437A JP 2012555437 A JP2012555437 A JP 2012555437A JP 2013520979 A5 JP2013520979 A5 JP 2013520979A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- chimeric molecule
- syndrome
- thrombosis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 208000007536 Thrombosis Diseases 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000024203 complement activation Effects 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 206010040047 Sepsis Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 4
- 102000016550 Complement Factor H Human genes 0.000 claims 4
- 108010053085 Complement Factor H Proteins 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 230000008021 deposition Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000037803 restenosis Diseases 0.000 claims 4
- 201000003068 rheumatic fever Diseases 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 206010003178 Arterial thrombosis Diseases 0.000 claims 2
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 206010028851 Necrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 238000007887 coronary angioplasty Methods 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 2
- 206010014665 endocarditis Diseases 0.000 claims 2
- 229950003499 fibrin Drugs 0.000 claims 2
- 108090000062 ficolin Proteins 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000010849 intracranial embolism Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000002537 thrombolytic effect Effects 0.000 claims 2
- 201000005060 thrombophlebitis Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 206010000228 Abortion infected Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004881 Amebiasis Diseases 0.000 claims 1
- 206010001980 Amoebiasis Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 claims 1
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 claims 1
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108010028778 Complement C4 Proteins 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 208000000289 Esophageal Achalasia Diseases 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 1
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010030136 Oesophageal achalasia Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 108050007539 Plasma protease C1 inhibitor Proteins 0.000 claims 1
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 102000029301 Protein S Human genes 0.000 claims 1
- 108010066124 Protein S Proteins 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 208000002359 Septic Abortion Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010058990 Venous occlusion Diseases 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 208000027207 Whipple disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 201000000621 achalasia Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 201000005008 bacterial sepsis Diseases 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 210000000918 epididymis Anatomy 0.000 claims 1
- 201000010063 epididymitis Diseases 0.000 claims 1
- 208000001606 epiglottitis Diseases 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 201000001505 hemoglobinuria Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 206010035653 pneumoconiosis Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 239000003998 snake venom Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 1
- 208000000143 urethritis Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31102410P | 2010-03-05 | 2010-03-05 | |
| US61/311,024 | 2010-03-05 | ||
| EP10155621 | 2010-03-05 | ||
| EP10155621.5 | 2010-03-05 | ||
| PCT/EP2011/053309 WO2011107591A1 (en) | 2010-03-05 | 2011-03-04 | Chimeric inhibitor molecules of complement activation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520979A JP2013520979A (ja) | 2013-06-10 |
| JP2013520979A5 true JP2013520979A5 (enExample) | 2014-04-17 |
| JP6148013B2 JP6148013B2 (ja) | 2017-06-14 |
Family
ID=43901202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555437A Active JP6148013B2 (ja) | 2010-03-05 | 2011-03-04 | 補体活性化のキメラ抑制分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US9815876B2 (enExample) |
| EP (2) | EP2542569B1 (enExample) |
| JP (1) | JP6148013B2 (enExample) |
| AU (1) | AU2011222883B2 (enExample) |
| CA (1) | CA2791841C (enExample) |
| WO (1) | WO2011107591A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3028716B1 (en) | 2006-10-10 | 2020-09-16 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
| CA2791841C (en) | 2010-03-05 | 2023-01-03 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| WO2012095519A1 (en) * | 2011-01-13 | 2012-07-19 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie | Potent inhibitors of complement activation |
| FR2982490A1 (fr) * | 2011-11-14 | 2013-05-17 | Centre Nat Rech Scient | Utilisation de la proteine s pour traiter le cancer. |
| WO2013142362A1 (en) * | 2012-03-19 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
| CN118924900A (zh) * | 2012-06-18 | 2024-11-12 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
| SI2968434T1 (sl) | 2013-03-15 | 2017-11-30 | Shire Viropharma Incorporated, | C1-INH sestavki za uporabo pri preprečevanju in zdravljenju hereditarnega angioedema (HAE) |
| EP2821076A1 (en) * | 2013-07-02 | 2015-01-07 | Stallergenes Sa | C1q as a therapeutic agent of allergy and/or asthma |
| WO2016115616A1 (en) * | 2015-01-21 | 2016-07-28 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Inhibition of cellular proteases as treatment for influenza |
| RU2727411C2 (ru) | 2015-09-24 | 2020-07-21 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиция и способ для лечения заболевания, опосредованного комплементом |
| HK1257426A1 (zh) * | 2015-10-30 | 2019-10-18 | 豪夫迈‧罗氏有限公司 | 抗-因子d抗体制剂 |
| JPWO2018070521A1 (ja) * | 2016-10-14 | 2019-08-15 | 公立大学法人福島県立医科大学 | 補体の活性化経路を阻害する融合ポリペプチド |
| JP6143209B1 (ja) * | 2016-10-31 | 2017-06-07 | 国立大学法人大阪大学 | 自己免疫疾患用または難治性血管炎用の治療剤、および、これらの疾患の診断のためのデータの取得方法 |
| IT201600121482A1 (it) * | 2016-11-30 | 2018-05-30 | Univ Degli Studi Di Verona | Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme |
| GB201704071D0 (en) * | 2017-03-14 | 2017-04-26 | Univ Newcastle | Recombinant mature complement factor 1 |
| JP2020521723A (ja) * | 2017-05-31 | 2020-07-27 | オーリン バイオテック インコーポレイテッドＡｕｒｉｎ Ｂｉｏｔｅｃｈ Ｉｎｃ． | 悪液質の診断方法および治療方法 |
| CA3070230A1 (en) | 2017-07-24 | 2019-01-31 | Rutgers, The State University Of New Jersey | Phosphatidylserine targeting fusion molecules and methods for their use |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| WO2020213004A1 (en) * | 2019-04-13 | 2020-10-22 | National Centre For Cell Science | Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system |
| IL299048A (en) | 2020-06-14 | 2023-02-01 | Vertex Pharma | Variants of complement factor - 1 fusion structures and preparations containing them and their uses |
| CN113307857B (zh) * | 2021-01-14 | 2022-11-01 | 艾时斌 | 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白 |
| EP4286406A4 (en) * | 2021-01-29 | 2025-07-23 | Illimis Therapeutics Inc | FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY |
| WO2025054327A1 (en) * | 2023-09-05 | 2025-03-13 | The Regents Of The University Of Colorado, A Body Corporate | Constructs, compositions, and methods for reducing hypersensitivity reactions to therapeutic agents |
| EP4559472A1 (en) * | 2023-11-24 | 2025-05-28 | Universität Ulm | Complement modulator |
| WO2025109172A1 (en) * | 2023-11-24 | 2025-05-30 | Universität Ulm | Complement modulator |
| KR20250136262A (ko) | 2024-03-06 | 2025-09-16 | 일리미스테라퓨틱스 주식회사 | 엔지니어링된 tam 수용체 리간드 폴리펩티드 및 이의 용도 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4203570A (en) | 1978-08-23 | 1980-05-20 | The Western States Machine Company | Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4546082A (en) | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| WO1984004330A1 (en) | 1983-04-22 | 1984-11-08 | Amgen | Secretion of exogenous polypeptides from yeast |
| NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
| AU607398B2 (en) | 1985-08-29 | 1991-03-07 | Genencor Inc. | Heterologous polypeptides expressed in filamentous fungi, processes for making same, and vectors for making same |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| HU206897B (en) | 1985-10-25 | 1993-01-28 | Zymogenetics Inc | Process for utilizing bar-1 gen for selecting strange proteins |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| GB8615942D0 (en) | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
| NZ221259A (en) | 1986-07-31 | 1990-05-28 | Calgene Inc | Seed specific transcriptional regulation |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5024947A (en) | 1987-07-24 | 1991-06-18 | Cetus Corporation | Serum free media for the growth on insect cells and expression of products thereby |
| DE3856247T2 (de) | 1987-07-24 | 1999-04-29 | Chiron Corp., Emeryville, Calif. | Züchtung von insektenzellen mit airlift-reaktoren |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| JP2703598B2 (ja) | 1987-09-04 | 1998-01-26 | ノボ―ノルディスク アクティーゼルスカブ | アスペルギルス菌中でのタンパク質生産物の生産方法およびアスペルギルス菌中で使用するためのプロモーター |
| DK463887D0 (da) | 1987-09-07 | 1987-09-07 | Novo Industri As | Gaerleader |
| US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| GB8826446D0 (en) | 1988-11-11 | 1988-12-14 | Agricultural & Food Res | Peptide production |
| WO1990005783A1 (en) | 1988-11-18 | 1990-05-31 | Cetus Corporation | Insect signal peptide mediated secretion of recombinant proteins |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| AU5526690A (en) | 1989-04-19 | 1990-11-29 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| GB8910962D0 (en) | 1989-05-12 | 1989-06-28 | Natural Environment Res | Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells |
| DE69026306T2 (de) | 1989-05-27 | 1996-10-17 | Seikagaku Kogyo Co Ltd | Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine. |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
| US5073964A (en) | 1989-08-04 | 1991-12-17 | Aware, Inc. | Signal processing device and method |
| US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
| US5023328A (en) | 1989-08-04 | 1991-06-11 | The Texas A&M University System | Lepidopteran AKH signal sequence |
| US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| EP0513332A4 (en) | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
| DK300090D0 (da) | 1990-12-19 | 1990-12-19 | Novo Nordisk As | Fremgangsmaade til fremstilling af leadersekvenser |
| JPH06507307A (ja) | 1991-01-11 | 1994-08-25 | アメリカン・レツド・クロス | トランスジェニック動物の乳腺組織における活性ヒトプロテインｃの発現 |
| CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| WO1994004193A1 (en) | 1992-08-21 | 1994-03-03 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| IL104734A0 (en) | 1993-02-15 | 1993-06-10 | Univ Bar Ilan | Bioactive conjugates of cellulose with amino compounds |
| AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| WO1995000162A1 (en) | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| ATE214940T1 (de) | 1993-11-10 | 2002-04-15 | Enzon Inc | Verbesserte interferon-polymerkonjugate |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5473034A (en) | 1994-03-18 | 1995-12-05 | Hyogo Prefectural Government | Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| AU2826495A (en) | 1994-06-02 | 1996-01-04 | Enzon, Inc. | Method of solubilizing substantially water insoluble materials |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
| US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| WO1996040791A1 (en) | 1995-06-07 | 1996-12-19 | Novo Nordisk A/S | Modification of polypeptides |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| DE69736780T2 (de) | 1996-08-02 | 2007-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer |
| EP0921817B1 (en) | 1997-01-29 | 2001-03-28 | PolyMASC Pharmaceuticals plc | Pegylation process |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| AU744085B2 (en) | 1997-06-06 | 2002-02-14 | Kyowa Hakko Kirin Co., Ltd. | Chemically modified polypeptides |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| WO2002006460A2 (en) | 2000-07-13 | 2002-01-24 | Jens Christian Jensenius | Masp-2, a complement-fixing enzyme, and uses for it |
| CN1694961A (zh) * | 2002-09-10 | 2005-11-09 | 内蒂穆恩公司 | 胶原凝集素－补体激活蛋白嵌合体 |
| EP2292259A3 (en) | 2002-11-15 | 2011-03-23 | MUSC Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| US20060275764A1 (en) * | 2002-12-03 | 2006-12-07 | Aarhus Universitet | Method for determining predisposition to manifestation of immune system related diseases |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2007047995A2 (en) * | 2005-10-21 | 2007-04-26 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| AU2007261315B2 (en) * | 2006-06-21 | 2012-10-25 | Musc Foundation For Research Development | Targeting complement factor H for treatment of diseases |
| CA2791841C (en) * | 2010-03-05 | 2023-01-03 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| US9417039B2 (en) | 2015-01-07 | 2016-08-16 | Victor Rowley | Broadhead arrow |
-
2011
- 2011-03-04 CA CA2791841A patent/CA2791841C/en active Active
- 2011-03-04 JP JP2012555437A patent/JP6148013B2/ja active Active
- 2011-03-04 WO PCT/EP2011/053309 patent/WO2011107591A1/en not_active Ceased
- 2011-03-04 AU AU2011222883A patent/AU2011222883B2/en active Active
- 2011-03-04 EP EP11706287.7A patent/EP2542569B1/en active Active
- 2011-03-04 US US13/582,814 patent/US9815876B2/en active Active
- 2011-03-04 EP EP20195907.9A patent/EP3815708A1/en active Pending
-
2014
- 2014-12-30 US US14/585,369 patent/US9573984B2/en active Active
-
2017
- 2017-01-06 US US15/400,412 patent/US10294286B2/en active Active
- 2017-10-11 US US15/729,924 patent/US10752661B2/en active Active
-
2020
- 2020-07-16 US US16/930,973 patent/US11453709B2/en active Active
-
2022
- 2022-08-09 US US17/818,583 patent/US11945848B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520979A5 (enExample) | ||
| JP2012533288A5 (enExample) | ||
| JP7686689B2 (ja) | アネキシンｖの製造プロセス | |
| JP5522723B2 (ja) | 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法 | |
| US9856326B2 (en) | Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies | |
| US9920098B2 (en) | Protein ligand for affinity isolation matrix | |
| JP6426618B2 (ja) | 新規なピリジン誘導体 | |
| JP2014504265A5 (enExample) | ||
| JP2011502479A5 (enExample) | ||
| Heredia et al. | Calcium-dependent conformational change and thermal stability of the isolated PsbO protein detected by FTIR spectroscopy | |
| Oganesyan et al. | Fibronectin type III domains engineered to bind CD40L: cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of two complexes | |
| JP2013516991A5 (enExample) | ||
| Johnson et al. | Structural and biophysical characterization of an epitope-specific engineered Fab fragment and complexation with membrane proteins: implications for co-crystallization | |
| Grimm et al. | Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity | |
| WO2014022648A2 (en) | Reversible regulation of intein activity through engineered new zinc binding domain | |
| JP2012514465A5 (enExample) | ||
| JPH05505940A (ja) | 組換え蛋白類を精製する改良方法および該方法で有用な化合物類 | |
| CN102732507B (zh) | 一种改进的dna配基筛选方法 | |
| US20220098590A1 (en) | Method for Obtaining Aptamers | |
| JP2007174957A5 (enExample) | ||
| Tran et al. | ARR1 and AHP interactions in the multi-step phosphorelay system | |
| Landgraf et al. | From biology to biotechnology: disulfide bond formation in escherichia coli | |
| CN102732524A (zh) | 类HRG的七鳃鳗Lj-RGD3全RGD缺失突变体Lj-112在抗肿瘤药物中的应用 | |
| JP2012130294A (ja) | 抗体結合タンパク質およびその製造方法 | |
| CN109157654B (zh) | Tmx1的用途 |